Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

Marcellin, Patrick; Bonino, Ferruccio; Lau, George; Farci, Patrizia; Yurdaydın, Cihan; Piratvisuth, Teerha; Jin, Rui; Gürel, Selım; Lu, Zhongmin; Wu, Jinhua; Popescu, M.; Hadziyannis, Stephanos J.

doi:10.1053/j.gastro.2009.03.006

Cited by 298 publications

(290 citation statements)

References 31 publications

Supporting

Mentioning

267

Contrasting

Unclassified

Order By: Relevance

“…Even with the extension of therapy duration to 48 weeks, it has been shown that the HBeAg seroconversion rate (33%), which correlates with SVR, is almost identical to that of conventional IFN-a as determined in a meta-analysis (32%). In addition, after 3 years of follow-up for HBeAg-negative patients with lower baseline HBV DNA levels, the rate of undetectable HBV DNA by PCR is only 18% (Marcellin et al, 2009).…”

Section: Hepatitis Bmentioning

confidence: 99%

IFN‐α subtypes: distinct biological activities in anti‐viral therapy

Gibbert

Schlaak

Yang

et al. 2013

British J Pharmacology

154

138

View full text Add to dashboard Cite

During most viral infections, the immediate host response is characterized by an induction of type I IFN. These cytokines have various biological activities, including anti‐viral, anti‐proliferative and immunomodulatory effects. After induction, they bind to their IFN‐α/β receptor, which leads to downstream signalling resulting in the expression of numerous different IFN‐stimulated genes. These genes encode anti‐viral proteins that directly inhibit viral replication as well as modulate immune function. Thus, the induction of type I IFN is a very powerful tool for the host to fight virus infections. Many viruses evade this response by various strategies like the direct suppression of IFN induction or inhibition of the IFN signalling pathway. Therefore, the therapeutic application of exogenous type I IFN or molecules that induce strong IFN responses should be of great potential for future immunotherapies against viral infections. Type I IFN is currently used as a treatment in chronic hepatitis B and C virus infection, but as yet is not widely utilized for other viral infections. One reason for this restricted clinical use is that type I IFN belongs to a multigene family that includes 13 different IFN‐α subtypes and IFN‐β, whose individual anti‐viral and immunomodulatory properties have so far not been investigated in detail to improve IFN therapy against viral infections in humans. In this review, we summarize the recent achievements in defining the distinct biological functions of type I IFN subtypes in cell culture and in animal models of viral infection as well as their clinical usage in chronic hepatitis virus infections.

show abstract

Section: Hepatitis Bmentioning

confidence: 99%

IFN‐α subtypes: distinct biological activities in anti‐viral therapy

Gibbert

Schlaak

Yang

et al. 2013

British J Pharmacology

154

138

View full text Add to dashboard Cite

show abstract

“…3,23 For HBeAg-negative patients that receive peginterferon, most who maintains HBV-DNA suppression < 2,000 UI/mL for one year after treatment, will sustain viral suppression up to the third year. 24 Consequently, the use of HBV-DNA levels as a surrogate marker for treatment response is valid only if viral suppression is maintained during NA treatment. As for treatment with peginterferon of HBeAg-negative patients, the sustained suppression of the HBV-DNA up to one year after treatment is also a reasonable response marker.…”

Section: Viral Suppression Of Hbv-dnamentioning

confidence: 99%

“…8,[31][32][33][34][35] Among patients who received a one-year treatment with PEG-IFN, 9%-11% lost HBsAg three years after the end of treatment. 24,30 Therefore, predictors for disappearance of HBsAg during treatment are more important than those for seroconversion, but a longer-term follow-up is necessary for their assessment.…”

Section: Sustained Response Versus Maintained Responsementioning

confidence: 99%

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Ferreira

Tenore

2010

Braz J Infect Dis

View full text Add to dashboard Cite

The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotyp

show abstract

“…Moreover, HBsAg loss occurs rarely with a yearly rate of 1-3% [8]. Alternatively, a 1-year course of peginterferon-a (PEG-IFN) therapy induces a higher rate of HBeAg seroconversion (30%), a potential for the development of SVR (20-30%), and a high yearly rate of HBsAg in SVRs (10-15%) [20][21][22][23][24].…”

Section: Quantitative Hbsag In Peginterferon and Nucleos(t)ide Analog Tmentioning

confidence: 99%